Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 1/20 | 0.52 |
| ▸ | CA2 | P00918 | 1/20 | 0.52 |
| ▸ | CA9 | Q16790 | 1/20 | 0.52 |
| ▸ | F2 | P00734 | 1/20 | 0.31 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.31 |
| ▸ | PRSS2 | P07478 | 1/20 | 0.31 |
| ▸ | PRSS3 | P35030 | 1/20 | 0.31 |
| ▸ | USP2 | O75604 | 1/20 | 0.30 |
| ▸ | TSHR | P16473 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL778173 | 0.84 | CA1 (0.62) | CA1CA2CA9 | |
| SCHEMBL21084880 | 0.78 | CA1 (0.32) | CA1CA2CA9 | |
| SCHEMBL17456375 | 0.76 | CA1 (0.48) | CA1CA2CA9 | |
| SCHEMBL778644 | 0.75 | CA1 (0.46) | CA1CA2CA9 | |
| SCHEMBL17456628 | 0.75 | CA1 (0.46) | CA1CA2CA9 | |
| SCHEMBL585314 | 0.74 | CA1 (0.56) | CA1CA2CA9USP2TSHR | |
| SCHEMBL778461 | 0.73 | PTGS2 (0.31) | — | |
| SCHEMBL16140150 | 0.70 | CA1 (0.59) | CA1CA2CA9 | |
| SCHEMBL1401780 | 0.70 | CA1 (0.52) | CA1CA2CA9 | |
| SCHEMBL9957399 | 0.70 | CA1 (0.46) | CA1CA2CA9F2PRSS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230227442-A1 | HETEROALKYL DIHYDROQUINOLINE SULFONAMIDE COMPOUNDS | AMGEN INC. (US) | 2023-07-20 | — | — | US | disclosed |
| US-20220306604-A1 | CYCLOBUTYL DIHYDROQUINOLINE SULFONAMIDE COMPOUNDS | AMGEN INC. (US) | 2022-09-29 | — | — | US | disclosed |
| US-20220149436-A1 | NON-AQUEOUS LIQUID ELECTROLYTE AND NON-AQUEOUS LIQUID ELECTROLYTE SECONDARY BATTERY | MITSUBISHI CHEMICAL CORPORATION (JP) | 2022-05-12 | — | — | US | disclosed |
| WO-2021252820-A1 | CYCLOBUTYL DIHYDROQUINOLINE SULFONAMIDE COMPOUNDS | AMGEN INC. (US) | 2021-12-16 | — | — | WO | disclosed |
| EP-3621141-A1 | NON-AQUEOUS LIQUID ELECTROLYTE AND NON-AQUEOUS LIQUID ELECTROLYTE SECONDARY BATTERY | MITSUBISHI CHEMICAL CORPORATION (JP) | 2020-03-11 | — | — | EP | disclosed |
| US-20190229372-A1 | NON-AQUEOUS LIQUID ELECTROLYTE AND NON-AQUEOUS LIQUID ELECTROLYTE SECONDARY BATTERY | MITSUBISHI CHEMICAL CORPORATION (JP) | 2019-07-25 | — | — | US | disclosed |
| US-10333172-B2 | Non-aqueous liquid electrolyte and non-aqueous liquid electrolyte secondary battery | MITSUBISHI CHEMICAL CORPORATION (JP) | 2019-06-25 | — | — | US | disclosed |
| US-10290901-B2 | — | — | 2019-05-14 | — | — | US | disclosed |
| US-9608291-B2 | Non-aqueous liquid electrolyte and non-aqueous liquid electrolyte secondary battery | MITSUBISHI CHEMICAL CORPORATION (JP) | 2017-03-28 | — | — | US | disclosed |
| US-20170084955-A1 | NON-AQUEOUS LIQUID ELECTROLYTE AND NON-AQUEOUS LIQUID ELECTROLYTE SECONDARY BATTERY | MITSUBISHI CHEMICAL CORPORATION (JP) | 2017-03-23 | — | — | US | disclosed |
| US-9343777-B2 | Non-aqueous liquid electrolyte and non-aqueous liquid electrolyte secondary battery | MITSUBISHI CHEMICAL CORPORATION (JP) | 2016-05-17 | — | — | US | disclosed |
| US-9252457-B2 | Non-aqueous liquid electrolyte and non-aqueous liquid electrolyte secondary battery | MITSUBISHI CHEMICAL CORPORATION (JP) | 2016-02-02 | — | — | US | disclosed |
| US-20150188192-A1 | NON-AQUEOUS LIQUID ELECTROLYTE AND NON-AQUEOUS LIQUID ELECTROLYTE SECONDARY BATTERY | MITSUBISHI CHEMICAL CORPORATION (JP) | 2015-07-02 | — | — | US | disclosed |
| US-20150056503-A1 | NON-AQUEOUS LIQUID ELECTROLYTE AND NON-AQUEOUS LIQUID ELECTROLYTE SECONDARY BATTERY | MITSUBISHI CHEMICAL CORPORATION (JP) | 2015-02-26 | — | — | US | disclosed |
| US-20120177988-A1 | NON-AQUEOUS LIQUID ELECTROLYTE AND NON-AQUEOUS LIQUID ELECTROLYTE SECONDARY BATTERY | MITSUBISHI CHEMICAL CORPORATION (JP) | 2012-07-12 | — | — | US | disclosed |
| US-20120070731-A1 | NON-AQUEOUS LIQUID ELECTROLYTE AND NON-AQUEOUS LIQUID ELECTROLYTE SECONDARY BATTERY | MITSUBISHI CHEMICAL CORPORATION (JP) | 2012-03-22 | — | — | US | disclosed |
| US-7794876-B2 | Pentafluorophenyloxy compound, and nonaqueous electrolyte solution and lithium secondary battery using same | UBE INDUSTRIES, LTD. (JP) | 2010-09-14 | — | — | US | disclosed |
| US-20090325065-A1 | NON-AQUEOUS LIQUID ELECTROLYTE AND NON-AQUEOUS LIQUID ELECTROLYTE SECONDARY BATTERY | MITSUBISHI CHEMICAL CORPORATION (JP) | 2009-12-31 | — | — | US | disclosed |
| EP-2012386-A1 | NONAQUEOUS ELECTROLYTE SOLUTION AND NONAQUEOUS ELECTROLYTE SECONDARY BATTERY | Mitsubishi Chemical Corporation (JP) | 2009-01-07 | — | — | EP | disclosed |
| US-20080107969-A1 | Pentafluorophenyl Methyl Oxalate; good electrical, cycling and storage properties; reacting pentafluorophenol with ethyl chloroglyoxylate | UBE INDUSTRIES, LTD. (JP) | 2008-05-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230227442-A1 | HETEROALKYL DIHYDROQUINOLINE SULFONAMIDE COMPOUNDS | SCN7A, TRPV1, SCNN1A | CA1 2002/4885CA2 203/4885CA9 1828/4885 |
| US-20220306604-A1 | CYCLOBUTYL DIHYDROQUINOLINE SULFONAMIDE COMPOUNDS | TRPV1, SCN7A, TRPA1 | CA1 1344/4885CA2 196/4885CA9 2171/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.